Revolution Medicines, Inc.

RVMD

$69.14

Name : Revolution Medicines, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $13,366,131,712.00

EPSttm : -5.19

Revolution Medicines, Inc.

$69.14

2.05%

$1.39

Float Short %

10.75

Margin Of Safety %

Put/Call OI Ratio

0.37

EPS Next Q Diff

0.03

EPS Last/This Y

-1.91

EPS This/Next Y

-0.72

Price

69.11

Target Price

80.95

Analyst Recom

Performance Q

89.22

Relative Volume

1.22

Beta

0.95

Ticker: RVMD

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-10-20	RVMD	54.01	0.40	1.36	40687
2025-10-21	RVMD	53.48	0.39	0.07	40527
2025-10-22	RVMD	53.01	0.39	0.06	40685
2025-10-23	RVMD	53.4	0.39	0.00	40638
2025-10-24	RVMD	54.46	0.39	0.05	40656
2025-10-27	RVMD	58.04	0.39	0.12	40700
2025-10-28	RVMD	58.16	0.39	0.10	40930
2025-10-29	RVMD	58.05	0.39	0.15	40932
2025-10-30	RVMD	58.84	0.39	0.24	40977
2025-10-31	RVMD	58.8	0.39	0.14	41137
2025-11-03	RVMD	59.33	0.38	0.02	41286
2025-11-04	RVMD	58.56	0.39	0.38	41259
2025-11-05	RVMD	59.28	0.39	2.60	41341
2025-11-06	RVMD	61.42	0.39	0.90	41594
2025-11-07	RVMD	61	0.39	0.02	41516
2025-11-10	RVMD	62.72	0.37	0.09	43126
2025-11-11	RVMD	64.13	0.37	0.05	43176
2025-11-12	RVMD	65.82	0.37	0.01	43268
2025-11-13	RVMD	64.37	0.37	0.18	43497
2025-11-14	RVMD	67.77	0.37	0.31	43537
2025-11-17	RVMD	69.14	0.37	0.30	44118
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-10-20	RVMD	54.01	-49.5	-402.6	-5.31
2025-10-21	RVMD	53.49	-49.5	-389.6	-5.31
2025-10-22	RVMD	52.98	-49.9	-389.8	-5.32
2025-10-23	RVMD	53.41	-49.9	-418.5	-5.32
2025-10-24	RVMD	54.47	-49.9	-436.6	-5.32
2025-10-27	RVMD	58.00	-49.9	-510.1	-5.32
2025-10-28	RVMD	58.17	-49.9	-410.2	-5.32
2025-10-29	RVMD	58.04	-49.9	-401.6	-5.32
2025-10-30	RVMD	58.87	-49.9	-427.3	-5.32
2025-10-31	RVMD	58.84	-49.9	-403.6	-5.32
2025-11-03	RVMD	59.33	-49.9	-419.8	-5.32
2025-11-04	RVMD	58.54	-49.9	-384.0	-5.32
2025-11-05	RVMD	59.35	-49.9	-426.4	-5.32
2025-11-06	RVMD	61.39	-49.9	-461.3	-5.32
2025-11-07	RVMD	61.01	-49.9	-254.6	-5.32
2025-11-10	RVMD	62.73	-36.6	-307.8	-5.32
2025-11-11	RVMD	64.08	-40.3	-299.0	-5.49
2025-11-12	RVMD	65.81	-40.3	-305.5	-5.49
2025-11-13	RVMD	64.36	-40.3	-230.7	-5.49
2025-11-14	RVMD	67.74	-40.3	-343.8	-5.49
2025-11-17	RVMD	69.11	-40.3	-294.6	-5.49
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-10-20	RVMD	-0.88	-2.18	11.09
2025-10-21	RVMD	-0.88	-2.18	11.09
2025-10-22	RVMD	-0.88	-2.18	11.09
2025-10-23	RVMD	-0.88	-2.18	11.09
2025-10-24	RVMD	-0.88	-2.18	11.09
2025-10-27	RVMD	-0.88	-2.25	11.95
2025-10-28	RVMD	-0.88	-2.25	11.96
2025-10-29	RVMD	-0.88	-2.25	11.96
2025-10-30	RVMD	-0.88	-2.25	11.96
2025-10-31	RVMD	-0.88	-2.25	11.95
2025-11-03	RVMD	-0.88	-2.18	11.95
2025-11-04	RVMD	-0.88	-2.18	11.95
2025-11-05	RVMD	-0.88	-2.18	11.95
2025-11-06	RVMD	-0.88	-2.18	11.95
2025-11-07	RVMD	-0.88	-2.18	11.95
2025-11-10	RVMD	-0.85	-1.90	11.56
2025-11-11	RVMD	-0.85	-1.90	11.56
2025-11-12	RVMD	-0.85	-1.90	10.76
2025-11-13	RVMD	-1.00	-1.90	10.76
2025-11-14	RVMD	-1.00	-1.90	10.75
2025-11-17	RVMD	-1.09	4.43	10.75
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-1.61

Avg. EPS Est. Current Quarter

-1.57

Avg. EPS Est. Next Quarter

-1.58

Insider Transactions

-1.09

Institutional Transactions

4.43

Beta

0.95

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

-0.1

Max Drawdown 5-Year %

-73.3

Target Price

80.95

P/E

Forward P/E

PEG

P/S

P/B

8.21

P/Free Cash Flow

EPS

-5.18

Average EPS Est. Cur. Y

-5.49

EPS Next Y. (Est.)

-6.21

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

1.22

Return on Equity vs Sector %

-87.1

Return on Equity vs Industry %

-72.2

EPS 1 7Days Diff

-0.2

EPS 1 30Days Diff

-0.19

EBIT Estimation

-294.6

Revolution Medicines, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 809

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

stock quote shares RVMD – Revolution Medicines, Inc. Stock Price stock today

news today RVMD – Revolution Medicines, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch RVMD – Revolution Medicines, Inc. yahoo finance google finance

stock history RVMD – Revolution Medicines, Inc. invest stock market

stock prices RVMD premarket after hours

ticker RVMD fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: RVMD

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y